Prognostic Impact of Imaging Parameters in Patients With Primary Mitral Insufficiency by Prolapse (COHORTE-IM) (COHORTE-IM)

Prognostic Impact of Non-invasive Imaging Parameters (Cardiac Echocardiography and MRI) in Patients With Primary Mitral Insufficiency (MI) by Prolapse: Observational Cohort, Monocentric (COHORTE-IM)

Degenerative mitral insufficiency secondary to valve prolapse is the most common valve disease in Western countries. In the absence of specific treatment, it spontaneously progresses to heart failure and death when it is severe. Surgical mitral valve repair (or mitral plastic surgery) is the preferred treatment for primary mitral insufficiency by prolapse in case of severe leakage if associated with clinical and/or echocardiographic markers of poor prognosis (i.e., with high risk of morbi-mortality during their follow-up).

It is therefore essential to refine the risk stratification of these patients in order to identify at-risk patients who should potentially benefit earlier from invasive care (cardiac surgery), or conversely, close monitoring.

A number of echocardiographic and MRI parameters may have been associated with a poorer prognosis.

A cohort of patients with primary mitral insufficiency (MI) will be followed to study the relationships of a set of factors to patient prognosis.

Study Overview

• Status: Recruiting
• Conditions: Mitral Valve Insufficiency
• Intervention / Treatment: Other: Echocardiography and MRI

Detailed Description

Degenerative mitral insufficiency secondary to valve prolapse is the most common valve disease in Western countries. In the absence of specific treatment, it spontaneously progresses to heart failure and death when it is severe. Surgical mitral valve repair (or mitral plastic surgery) is the preferred treatment for primary mitral insufficiency by prolapse in case of severe leakage if associated with clinical and/or echocardiographic markers of poor prognosis (i.e., at high risk of morbi-mortality during their follow-up).

It is therefore essential to refine the risk stratification of these patients in order to identify at-risk patients who should potentially benefit earlier from invasive care (cardiac surgery), or conversely, close monitoring.

Beyond the regurgitation severity parameters, a number of regurgitation resonance parameters may have been associated with a poorer prognosis. These parameters include dilation of the left ventricle (increase of telesystolic diameter), of the left atrium, decrease of left ventricular ejection fraction (FE VG), and increase of pulmonary pressures (pulmonary hypertension). The relationship between left, right ventricular function, atrial function evaluated by new echocardiographic techniques (Speckle tracking, 3D) and prognosis has been poorly studied.

These new innovative techniques are now available in clinical routine and allow an evaluation of size and cardiac function parameters in a more reproducible way than conventional methods. The relationship between prognosis and the assessment of regurgitation severity by the convergence zone method (PISA method) has been well documented in the literature. However, the PISA method presents well-documented reproducibility problems. Other methods of quantification exist, either by echocardiography (qualitative, semi-quantitative and quantitative methods) or by MRI (quantitative methods). They are useful in clinical practice in a multiparametric approach, but their relationship to prognosis has been not well studied.

Thus, the prognostic impact of the following parameters must be studied:

• Echocardiographic and MRI parameters of primary insufficiency severity and their combination
• Ventricular and atrial functions measured by innovative echocardiographic methods (speckle tracking, 3D, left ventricular ejection performance parameters)
• The remodeling of cardiac cavities related to mitral insufficiency evaluated by echocardiography and MRI, apart from the diameter of the left ventricle and the size of the left atrium that has already been studied.

A cohort of patients with primary mitral insufficiency (MI) will be followed up to study the relationships of all these factors with patient prognosis. Part of this cohort will be retrospective, and part will be prospective.

• Study Type: Observational
• Enrollment (Estimated): 400

Contacts and Locations

• Study Contact: Name: Marie Paule LEBITASY, Md; Phone Number: +33 +33 3 20 22 52 69; Email: lootens.livia@ghicl.net
• Study Contact Backup: Name: Audrey Toia, CRA; Phone Number: +33 +33 3 20 22 57 33; Email: toia.audrey@ghicl.net

Study Locations

• France
  • Nord
    • Lomme, Nord, France, 59462
      • Recruiting
      • Lille Catholic Hospitals
      • Principal Investigator: Sylvestre Marechaux, Md, PhD
      • Contact: Marie Paule LEBITASY, Md; Phone Number: +33 +33 3 20 22 52 69; Email: lootens.livia@ghicl.net
      • Contact: Audrey Toia, CRA; Phone Number: +33 +33 3 20 22 57 33; Email: toia.audrey@ghicl.net

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: N/A

• Sampling Method: Non-Probability Sample

Study Population

Patients with primary mitral insufficiency by prolapse, who came or will come to the echocardiography laboratory of Saint Philibert Hospital for a Trans-Thoracic Echocardiography (TTE)

Description

Inclusion Criteria:

• Any patient with primary mitral insufficiency by prolapse (any grade) diagnosed by Trans-Thoracic Echocardiography (TTE)
• From November 2010 to April 2019 (retrospective cohort)
• From May 2019 to May 2024 (prospective cohort)
• No previous surgery of the mitral valve before the first ultrasound
• Adults
• Patient who has been informed and not opposed to the use of his or her medical record data

Exclusion Criteria:

• Secondary MI
• Primary MI without valve prolapse
• Active endocarditis
• Patient's refusal to participate in the study
• Patient under guardianship or curatorship

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Patient cohort; Routine follow-up of patients in the Cardiological Functional Explorations department - Valve Disease Centre for their primary mitral insufficiency by prolapse	Other: Echocardiography and MRI; Analysis of echocardiography and MRI parameters

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Time before the first morbi-mortality event	The impact of different parameters obtained by Doppler echocardiography (two-dimensional or three-dimensional mode) or MRI on the prognosis of time of the first morbi-mortality event arrival will be studied. Morbi-mortality is defined as the occurrence of at least one of the following events during follow-up: Death from any cause; Cardiovascular death defined as linked to heart failure, myocardial infarction, arrhythmia episode and sudden death; Hospitalization for heart failure; Occurrence of atrial fibrillation; Occurrence of a stroke	10 years

Collaborators and Investigators

• Sponsor: Lille Catholic University
• Collaborators: University Hospital, Lille
• Investigators: Principal Investigator: Sylvestre Marechaux, Md, PhD, Lille Catholic University

Study record dates

Study Major Dates

• Study Start (Actual): September 4, 2019
• Primary Completion (Estimated): September 1, 2034
• Study Completion (Estimated): September 1, 2034

Study Registration Dates

• First Submitted: May 22, 2019
• First Submitted That Met QC Criteria: May 22, 2019
• First Posted (Actual): May 23, 2019

Study Record Updates

• Last Update Posted (Actual): March 26, 2024
• Last Update Submitted That Met QC Criteria: March 25, 2024
• Last Verified: March 1, 2024

More Information

Terms related to this study

• Keywords: Prognosis; Mitral Valve Insufficiency; Imagery
• Additional Relevant MeSH Terms: Heart Diseases; Cardiovascular Diseases; Pathological Conditions, Anatomical; Heart Valve Diseases; Mitral Valve Insufficiency; Prolapse
• Other Study ID Numbers: RC-P0082

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No